Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections
Andrea Miró-Canturri, Andrea Vila-Domínguez, Marta Caretero-Ledesma, Rafael Ayerbe-Algaba, Jerónimo Pachón, Jiménez-Mejías Me, Younes Smani
Abstract
The development of new antimicrobial therapeutic strategies requires immediate attention to avoid the tens of millions of deaths predicted to occur by 2050 as a result of MDR bacterial infections. In this study, we assessed the antibacterial activity of three major tamoxifen metabolites, N -desmethyltamoxifen (DTAM), 4-hydroxytamoxifen (HTAM), and endoxifen (ENDX), against methicillin-resistant Staphylococcus epidermidis (MRSE) and Enterococcus spp. ( E. faecalis and E. faecium ).
Topics & Concepts
Staphylococcus epidermidisEnterococcus faecalisMicrobiologyEnterococcus faeciumAntimicrobialEnterococcusVancomycinMedicineRepurposingStaphylococcus aureusAntibioticsBiologyBacteriaGeneticsEcologyInflammatory mediators and NSAID effectsAntimicrobial Resistance in StaphylococcusAntifungal resistance and susceptibility